vibegron

Vibegron is a potent, selective beta-3 adrenergic receptor agonist used for the treatment of overactive bladder (OAB) in adults, including those with symptoms such as urge urinary incontinence, urgency, and urinary frequency. It is also indicated for use in men taking medications for benign prostatic hyperplasia (BPH) to help manage bladder symptoms. Vibegron works by relaxing the detrusor smooth muscle of the bladder during filling, thereby increasing bladder capacity and reducing episodes of urgency and incontinence. The drug acts by activating beta-3 adrenergic receptors on the bladder wall, leading to increased intracellular cAMP levels and subsequent muscle relaxation. Vibegron was first approved in Japan in 2018 and later received FDA approval under the brand name Gemtesa[1][2][3][4][5].

Brand names

Gemtesa

Other names

vibegron